Clinical Trial Update: Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM [Phase 2]

View source ↗

Summary

Phase 2b multicenter, randomized, double-blind trial evaluating three dose levels of PB1023 in adults with Type 2 Diabetes Mellitus has completed enrollment. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PB1023

Snippet

Sponsor: PhaseBio Pharmaceuticals Inc. | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED